245739-32-6

Basic information

• Product Name: Benzene, 1-bromo-2-[(1-methylethyl)thio]-
• CAS NO: 245739-32-6
• Molecular Formula: C9H11BrS
• Molecular Weight: 231.156
• Mol File: 245739-32-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzene, 1-bromo-2-[(1-methylethyl)thio]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-bromo-2-[(1-methylethyl)thio]-(245739-32-6)
• EPA Substance Registry System: Benzene, 1-bromo-2-[(1-methylethyl)thio]-(245739-32-6)

Safety Data

• Hazardous Substances Data: 245739-32-6(Hazardous Substances Data)

Upstream product

• 75-30-9 2-iodo-propane 
• 6320-02-1 o-bromothiophenol 
• 578-57-4 2-bromoanisole 
• 75-03-6 ethyl iodide 
• 75-26-3 isopropyl bromide 
• 1072-85-1 o-fluorobromobenzene 
• 75-33-2 2-propanethiol 

Downstream Products

• 1147014-96-7 4-((2-(isopropylthio)phenyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1379372-39-0 bis(2-isopropylthiophenyl)amine 
• 900174-43-8 1-bromo-2-(isopropylsulfonyl)benzene 

Relevant articles and documents

A new air-stable Si,S-chelating ligand for Ir-catalyzed directed: Ortho C-H borylation

A new air-stable Si,S-chelating ligand has been developed and used in an iridium-catalyzed ortho C-H borylation reaction with a broad substrate scope. This study provides the first example of using a sulfur-containing ligand in the catalytic C-H borylation process. It provides a rapid, efficient, and economical method for the preparation of organoboron compounds. This journal is

2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS

The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions.

PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS

The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.